Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Restricted accessResearch articleFirst published online February, 2025
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
The Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) is Italy's first cooperative oncology research group, evolving to conduct academic clinical trials since 1985. With 167 publications and collaborations with national and international partners, GOIRC has significantly impacted clinical practices. The group emphasizes training and has developed robust internal standard operative procedures (SOPs) to enhance data quality. GOIRC is poised to tackle future challenges in translational research, focusing on innovative trial designs, precision medicine, and leveraging different laboratory resources across its 42 units.
StranskyBde SouzaSJ.Modeling tumor evolutionary dynamics. Front Physiol2013; 3:10.3389/FPHYS.2012.00480.
6.
LeonettiABoydLGiulianiJ, et al. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on “preclinical and early-phase clinical pharmacology.”Expert Rev Clin Pharmacol2019; 12: 1033–1036.
7.
LemerySKeeganPPazdurR.First FDA approval agnostic of cancer site — when a biomarker defines the indication. N Engl J Med2017; 377: 1409–1412.
8.
Di LielloRPiccirilloMCArenareL, et al. Master protocols for precision medicine in oncology: overcoming methodology of randomized clinical trials. Life (Basel) 2021; 11: 1253.
9.
KaizerAMBelliHMMaZ, et al. Recent innovations in adaptive trial designs: A review of design opportunities in translational research. J Clin Transl Sci2023; 7: e125.
10.
WasonJMSJakiT.Optimal design of multi-arm multi-stage trials. Stat Med2012; 31: 4269–4279.
11.
FreidlinBKornELGrayR, et al. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res2008; 14: 4368–4371.
12.
RoystonPBarthelFMSParmarMKB, et al. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials2011; 12: 81.
13.
GilsonCChowdhurySParmarMKB, et al. Incorporating biomarker stratification into STAMPEDE: an adaptive multi-arm, multi-stage trial platform. Clin Oncol (R Coll Radiol)2017; 29: 778–786.
14.
CrouchLADoddLEProschanMA.Controlling the family-wise error rate in multi-arm, multi-stage trials. Clin Trials2017; 14: 237–245.
15.
BlenkinsopAParmarMKBChoodari-OskooeiB.Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework. Clin Trials2019; 16: 132–141.
16.
WasonJStallardNBowdenJ, et al. A multi-stage drop-the-losers design for multi-arm clinical trials. Stat Methods Med Res2017; 26: 508–524.
17.
WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent2014; 81: 14–18.
General Data Protection Regulation. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. Off J Eur Union2016; 119: 1–88.
20.
KayeJWhitleyEALundD, et al. Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet2014; 23: 141–146.
